Milrinone Tapering Protocol
For hemodynamically stable adults on milrinone, taper by reducing the infusion rate by 0.125-0.25 mcg/kg/min every 6-12 hours while monitoring hemodynamics closely, with the goal of discontinuation once the patient reaches 0.125-0.25 mcg/kg/min.
Tapering Strategy
The FDA label 1 and available evidence do not provide explicit tapering protocols, but based on the drug's pharmacokinetics and clinical practice patterns, here's the recommended approach:
Rate of Reduction
- Decrease by 0.125-0.25 mcg/kg/min per step
- Start from your current maintenance dose (typically 0.375-0.75 mcg/kg/min per FDA guidelines)
- The smaller decrement (0.125 mcg/kg/min) is preferred for patients who have been on higher doses or longer durations
Frequency of Adjustments
- Every 6-12 hours between dose reductions
- Milrinone has a half-life of 2.5 hours 1, meaning steady-state is achieved in approximately 12-15 hours
- Waiting 6-12 hours allows you to assess hemodynamic stability at each new dose level before further reduction
Monitoring During Taper
At each dose reduction, assess:
- Cardiac index (should remain >2.2 L/min/m²)
- Pulmonary capillary wedge pressure (should remain <18-20 mmHg)
- Blood pressure (watch for hypotension)
- Heart rate (monitor for compensatory tachycardia)
- Clinical signs of low cardiac output (cool extremities, altered mental status, decreased urine output)
Practical Tapering Example
For a patient on 0.5 mcg/kg/min:
- Reduce to 0.375 mcg/kg/min → wait 6-12 hours
- Reduce to 0.25 mcg/kg/min → wait 6-12 hours
- Reduce to 0.125 mcg/kg/min → wait 6-12 hours
- Discontinue completely
Critical Caveats
No loading dose reversal needed: Unlike the initiation where a 50 mcg/kg bolus is given 1, tapering does not require any reverse bolusing. Simply reduce the continuous infusion rate.
Renal function matters: If creatinine clearance is impaired, milrinone accumulates 1. In renal dysfunction, taper more slowly (every 12-24 hours) as the elimination half-life is significantly prolonged.
Duration of therapy consideration: Research shows milrinone was safely infused for 48 hours 2 to several days 3. Patients on prolonged therapy (>5-7 days) may benefit from slower tapering due to potential myocardial adaptation.
Watch for rebound: Studies demonstrate that hemodynamic improvements are sustained during infusion 2, 4, but discontinuation can lead to rapid return of symptoms within 2-4 hours given the short half-life 1. If hemodynamics deteriorate during tapering, return to the previous dose and optimize other heart failure therapies before attempting another taper.
Alternative to tapering: Research by Yancy et al. 5 showed that milrinone infusion without a loading dose achieved therapeutic levels within 2-3 hours, suggesting the drug reaches steady-state relatively quickly. This means abrupt discontinuation (rather than tapering) may be reasonable in truly stable patients, though gradual weaning remains the safer approach to identify marginal hemodynamic reserve.
When NOT to Taper
Per ACC/AHA guidelines 6, do not attempt tapering if:
- Patient remains stage D heart failure requiring bridge to transplant or mechanical circulatory support
- Ongoing end-organ hypoperfusion
- Patient is receiving milrinone for palliative purposes where symptom control is the goal
The guideline emphasizes that "the ongoing need for inotropic support and the possibility of discontinuation should be regularly assessed" 6, making systematic taper attempts appropriate in improving patients.